Literature DB >> 10051064

LC/ESI-MS allows simultaneous and specific quantification of SDZ RAD and cyclosporine, including groups of their metabolites in human blood.

G I Kirchner1, C Vidal, M Winkler, L Mueller, W Jacobsen, A Franzke, K F Sewing.   

Abstract

An analytic technique using liquid chromatography (LC) coupled with electrospray-mass spectrometry (ESI-MS) has been developed for the simultaneous determination of the new immunosuppressant SDZ RAD (40-O-[2-hydroxy)ethylrapamycin) and cyclosporine (Cs), including their metabolites in blood. With the time-sparing, automated on-line extraction technique, the recovery of SDZ RAD averaged 95% and that of Cs, 94%. The calibration lines were linear from 0.5 to 100 microg/L (r2 = 0.99) for SDZ RAD and from 10 to 1,000 microg/L (r2 = 0.99) for Cs. The method has been tested on blood samples from renal transplant recipients taken between 1 and 5 hours after oral SDZ RAD and Cs administration. In blood, we found the following metabolites: Hydroxy-SDZ RAD, dihydroxy-SDZ RAD, demethyl-SDZ RAD, and the ring-opened form of SDZ RAD. The main metabolite of SDZ RAD in blood was hydroxy-SDZ RAD. This novel LC/ESI-MS technique provided an excellent method for simultaneous quantitative monitoring of SDZ RAD and Cs, including their relevant groups of metabolites in patients treated simultaneously with these immunosuppressants.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10051064     DOI: 10.1097/00007691-199902000-00018

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  5 in total

1.  Pharmacokinetics of SDZ RAD and cyclosporin including their metabolites in seven kidney graft patients after the first dose of SDZ RAD.

Authors:  G I Kirchner; M Winkler; L Mueller; C Vidal; W Jacobsen; A Franzke; S Wagner; S Blick; M P Manns; K F Sewing
Journal:  Br J Clin Pharmacol       Date:  2000-11       Impact factor: 4.335

2.  Everolimus.

Authors:  Therese M Chapman; Caroline M Perry
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 3.  Clinical pharmacokinetics of everolimus.

Authors:  Gabriele I Kirchner; Ivo Meier-Wiedenbach; Michael P Manns
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

Review 4.  Ocular pharmacokinetics and safety of ciclosporin, a novel topical treatment for dry eye.

Authors:  Diane D-S Tang-Liu; Andrew Acheampong
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 5.577

5.  A new approach for the determination of immunosuppressive drugs using HPLC-MS/MS and Cs+ adducts.

Authors:  Patricia Kaiser; Theodorus Akerboom; William Graham Wood; Hans Reinauer
Journal:  Ger Med Sci       Date:  2006-01-18
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.